Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Met XL 23.75mg Tablet ER

Prescription Icon
Prescription Required

Marketer

Ajanta Pharma Ltd

Salt Composition

Metoprolol Succinate (23.75mg)

Overview Met XL 23.75mg Tablet ER

Extended-release Metoprolol succinate 23.75mg tablets (Met XL) are classified as beta-adrenergic blocking agents. This medication treats hypertension (high blood pressure), angina pectoris (chest pain from heart disease), and cardiac arrhythmias (irregular heartbeats). It's also used for migraine prevention and to reduce the risk of future strokes and myocardial infarctions. Met XL may be administered independently or in conjunction with other therapies. Dosage and frequency are individualized based on the condition being treated and its severity. Administration can be with or without food, but consistent daily timing is crucial for optimal efficacy. Full therapeutic benefit may not be evident for several weeks, and long-term use is often necessary. Continued use is vital even in the absence of symptoms; discontinuation can exacerbate the underlying condition. Common side effects include fatigue, headache, depressive symptoms, diarrhea, skin rash, bradycardia (slow heart rate), dizziness, and nausea – generally mild and transient. Less frequently, shortness of breath or hypotension (low blood pressure) may occur. Gradual dose escalation minimizes side effects. Report any persistent or bothersome adverse effects to your physician. Prior to initiation, disclose any liver impairment to your doctor. This medication isn't suitable for individuals with bradycardia, severe peripheral vascular disease, severe congestive heart failure, or hypotension. Pregnant or lactating women require medical consultation before use. A thorough discussion with your doctor is essential to determine suitability. Regular blood pressure monitoring is necessary to assess treatment effectiveness. Alcohol consumption should be limited due to potential exacerbation of side effects.

Uses of Met XL 23.75mg Tablet ER

Management of angina pectoris|Cardiac arrhythmia management|Mitigation of myocardial infarction|Hypertension therapy|Migraine prophylaxis

Major Benefits of Met XL 23.75mg Tablet ER:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Swallow the Met XL 23.75mg Extended-Release tablet whole; do not chew, crush, or break it. While it can be taken with or without food, consistent timing is recommended. To maximize effectiveness, avoid consuming Met XL 23.75mg Tablet ER with meals high in fat, including items like olive oil, nuts (especially Brazil nuts), dark chocolate, butter, and red meat.

Common Side effects of Met XL 23.75mg Tablet ER:

  • Tiredness
  • Dizziness
  • Depression
  • Breathlessness
  • Headache
  • Slow heart rate
  • Nausea
  • Rash
  • Diarrhea
  • Hypotension (low blood pressure)

How to use Met XL 23.75mg Tablet ER:

Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the 23.75mg Met XL extended-release tablet whole; do not crush, chew, or divide it. This medication can be taken with or without food, but consistent timing is recommended. Minimize consumption of high-fat foods, including olive oil, nuts (especially Brazil nuts), dark chocolate, butter, and fatty meats, while taking Met XL 23.75mg Tablet ER.

How Met XL 23.75mg Tablet ER works:

Extended-release Metoprolol succinate 23.75mg tablets are a sustained-action beta-adrenergic blocking agent targeted to the cardiovascular system. Their mechanism involves reducing cardiac rate and improving myocardial contractility, thereby enhancing circulatory efficiency.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Met XL 23.75mg Extended-Release Tablets with alcohol is unsafe.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Met XL 23.75mg tablets may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible dangers prior to prescribing this medication. Seek medical advice.

Breast feedingBreast feedingSAFE IF PRESCRIBED

Extended-release Met XL 23.75mg tablets are likely safe for breastfeeding mothers. Available human data indicates minimal risk to the infant.

DrivingDrivingUNSAFE

Extended-release Met XL 23.75mg tablets can cause drowsiness, blurred vision, and dizziness. Refrain from driving if you experience these effects.

KidneyKidneySAFE IF PRESCRIBED

Extended-release metformin 23.75 mg tablets (Met XL) are considered safe for individuals with impaired renal function. No alteration in the prescribed dosage of Met XL 23.75 mg tablets is necessary.

LiverLiverCAUTION

Extended-release metformin 23.75 mg tablets require careful administration in individuals with hepatic impairment. Dosage modification may be necessary. Physician consultation is advised.

What if you forget to take Met XL 23.75mg Tablet ER :

Should you forget a Met XL 23.75mg Extended-Release tablet, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Met XL 23.75mg Tablet ER

LabelValue
Type of Compound Ethanol and phenolic compounds
Addictive None.
Medication Classification HEART

FAQs on Met XL 23.75mg Tablet ER

Individual responses to Met XL 23.75mg Extended-Release tablets vary. Onset typically occurs within 15 minutes, although it may take up to two hours in some individuals. The therapeutic effect develops gradually, with peak effectiveness generally observed after one week of consistent use. Lack of immediate noticeable improvement with Met XL 23.75mg Extended-Release tablets is not cause for alarm; sustained benefit requires ongoing treatment.
Extended-release Met XL 23.75mg tablets are generally well-tolerated when administered according to a physician's instructions. However, abrupt cessation carries significant risks. Sudden discontinuation may trigger a rapid increase in heart rate and compromised cardiac function, posing a serious threat to individuals with heart failure and potentially resulting in myocardial infarction in some cases. Therefore, it is crucial to avoid abruptly stopping the medication and to continue taking it for the full prescribed period.
Extended-release Metoprolol Succinate 23.75mg tablets are classified as beta-blockers. While individual responses differ, these medications can sometimes disrupt sleep patterns in some individuals. Conversely, they may improve sleep in patients experiencing elevated heart rate or anxiety by reducing cardiac and nervous system activity. Consult your physician regarding any sleep-related concerns.
Consuming alcohol after taking a Met XL 23.75mg Tablet ER is inadvisable. Alcohol can intensify the medication's blood pressure reduction, potentially causing dangerously low blood pressure.
Met XL 23.75mg Tablet ER
66
MRP 80
17% off